From May 7 to 10 2025, Amsterdam (Netherlands) hosted the EASL Congress 2025, which stands out as Europe's largest event in hepatology. The congress attracted over 7,000 professionals, including clinicians, researchers, allied health professionals, patient representatives, and industry experts. THRIVE had the opportunity to present the project, engage with professionals in the area, and disseminate our initial findings to the EASL attendees.

THRIVE Presentation & Networking:

  • Networking session at the EASL Liver Tumours Track Hub, May 8th – 10:00, R. Pinyol, J.M. Llovet

Presentations by THRIVE Partners:

Awards:

  • General Session, 8th May – 11:15, J. Zucman-Rossi

Chaired sessions:

  • Liver Tumours: Experimental and Pathophysiology, 8th May – 17:00, J. Zucman-Rossi
  • General Hepatology: Late Breaker, 10th May 13:00, J. Zucman-Rossi

Basic Science Seminars – Liver Tumours:

  • Physiopathology of hepatocarcinogenesis in the presence & absence of cirrhosis, 7th May – 08:30, H. Reeves
  • Personalised precision medicine, 7th May – 18:45, J. Zucman-Rossi
  • Hepatoblastoma: from genomics to future therapies, 7th May – 18:55, T. Hirsch
  • Non-invasive fibrosis biomarkers and HistoIndex AI-based qFibrosis histology in MASH clinical trials (HARMONY trial), 10th May – 10:30, Q.M. Anstee

Presentations in:

Late breaker poster – 7th to 10th May. Spatial transcriptomics of the tumor microenvironment discriminates inflamed tumors responsive or resistant to atezo+bev in patients with advanced HCC. (LBP-029-YI), M. Piqué-Gili. Best of EASL Congress Slide Deck

  • Poster tours:   9th May – Track Hub 3 – Liver Tumours.
    • The intratumoral microbiome in HCC and its impact on treatment response. (SAT-113), U. Balaseviciute
    • Efficacy of WNTinib, a novel selective therapeutic for CTNNB1-mutant tumors, in preclinical models of hepatoblastoma. (TOP-128-YI), U. Balaseviciute
  • Poster – 8th May. Artificial intelligence-driven prediction of biology-related poor outcome & presence of vascular invasion in HCC (THU-078), A. Mesropian
  • Poster – 8th May. E7386 enhances lenvatinib’s antitumor efficacy and upregulates ATF4 signaling in preclinical models and human HCC (THU-077-YI), A. Mesropian
  • THRIVE Consortium  – Poster at the EASL Community Hub